UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

INFLAMMATORY BOWEL DISEASE RISK STRATIFICATION AND MANAGEMENT IN A COMMUNITY PRACTICE SETTING

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S33-S34

2022

Link zum Volltext

Verfügbarkeit prüfen

INFLAMMATORY BOWEL DISEASE RISK STRATIFICATION AND MANAGEMENT IN A COMMUNITY PRACTICE SETTING

Inflammatory bowel diseases, 2022-01, Vol.28 (Supplement_1), p.S33-S34

2022

Link zum Volltext

Verfügbarkeit prüfen

Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis

American journal of physiology. Heart and circulatory physiology, 2020-02, Vol.318 (2), p.H378-H390

2020

Link zum Volltext

Verfügbarkeit prüfen

CARDIAC TGFβ SIGNALING IS DECREASED IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

Journal of the American College of Cardiology, 2018-03, Vol.71 (11), p.A544-A544

2018

Link zum Volltext

Verfügbarkeit prüfen

Large-bore Aspiration Thrombectomy Efficacy and Safety Compared with Other Thrombectomy Modalities in the Treatment of Proximal Lower Extremity Deep Vein Thrombosis

Journal of vascular surgery, 2024-03, Vol.79 (3), p.e38-e39

2024

Link zum Volltext

Verfügbarkeit prüfen

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Blood advances, 2019-11, Vol.3 (21), p.3241-3247

2019

Link zum Volltext

Verfügbarkeit prüfen

Initial Analysis of Computer-aided Thrombectomy in the Management of Proximal Acute Lower Extremity Deep Venous Thrombosis

Journal of vascular surgery, 2023-09, Vol.78 (3), p.e48

2023

Link zum Volltext

Verfügbarkeit prüfen

The Use of Artificial Intelligence Technology in the Detection and Treatment of Pulmonary Embolism at a Tertiary Referral Center

Journal of vascular surgery, 2023-09, Vol.78 (3), p.e23

2023

Link zum Volltext

Verfügbarkeit prüfen

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Blood, 2022-11, Vol.140 (Supplement 1), p.11360-11361

2022

Link zum Volltext

Verfügbarkeit prüfen

Initial Outcomes In Iliofemoral Stenting In Acute Vs Chronic Deep Venous Thrombosis

Journal of vascular surgery, 2022-10, Vol.76 (4), p.e60-e61

2022

Link zum Volltext

Verfügbarkeit prüfen

Shorter Time to Assessment and Anticoagulation with Decreased Mortality in Patients with Pulmonary Embolism Following Implementation of Artificial Intelligence Software

Journal of vascular surgery. Venous and lymphatic disorders (New York, NY), 2024-05, Vol.12 (3)

2024

Link zum Volltext

Verfügbarkeit prüfen

Matched‐pair and propensity score comparisons of outcomes of patients with clinical stage I non–small cell lung cancer treated with resection or stereotactic radiosurgery

Cancer, 2013-08, Vol.119 (15), p.2683-2691

2013

Link zum Volltext

Verfügbarkeit prüfen

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Blood, 2022-11, Vol.140 (Supplement 1), p.8485-8488

2022

Link zum Volltext

Verfügbarkeit prüfen

Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial

Blood, 2020-11, Vol.136 (Supplement 1), p.13-13

2020

Link zum Volltext

Verfügbarkeit prüfen

Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

Blood, 2021-11, Vol.138 (Supplement 1), p.3201-3201

2021

Link zum Volltext

Verfügbarkeit prüfen

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Blood, 2019-11, Vol.134 (Supplement_1), p.3348-3348

2019

Link zum Volltext

Verfügbarkeit prüfen

Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B

Blood, 2020-11, Vol.136 (Supplement 1), p.2-3

2020

Link zum Volltext

Verfügbarkeit prüfen

Why plasma‐derived factor VIII?

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-05, Vol.25 (3), p.e183-e185

2019

Link zum Volltext

Verfügbarkeit prüfen

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Blood, 2020-11, Vol.136 (Supplement_2), p.LBA-6-LBA-6

2020

Link zum Volltext

Verfügbarkeit prüfen

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

Blood advances, 2023-10, Vol.7 (19), p.5671-5679

2023

Link zum Volltext

Verfügbarkeit prüfen

Postmastectomy Radiation Therapy and Breast Reconstruction: An Analysis of Complications and Patient Satisfaction

Annals of plastic surgery, 2010-05, Vol.64 (5), p.679-683

2010

Link zum Volltext

Verfügbarkeit prüfen

Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy

Blood advances, 2022-12

2022

Link zum Volltext

Verfügbarkeit prüfen

Matched-pair comparison of outcome of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7040-7040

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(24)
Bücher
(4)
audios
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

INFLAMMATORY BOWEL DISEASE RISK STRATIFICATION AND MANAGEMENT IN A COMMUNITY PRACTICE SETTING

INFLAMMATORY BOWEL DISEASE RISK STRATIFICATION AND MANAGEMENT IN A COMMUNITY PRACTICE SETTING

Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis

CARDIAC TGFβ SIGNALING IS DECREASED IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

Large-bore Aspiration Thrombectomy Efficacy and Safety Compared with Other Thrombectomy Modalities in the Treatment of Proximal Lower Extremity Deep Vein Thrombosis

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Initial Analysis of Computer-aided Thrombectomy in the Management of Proximal Acute Lower Extremity Deep Venous Thrombosis

The Use of Artificial Intelligence Technology in the Detection and Treatment of Pulmonary Embolism at a Tertiary Referral Center

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Initial Outcomes In Iliofemoral Stenting In Acute Vs Chronic Deep Venous Thrombosis

Shorter Time to Assessment and Anticoagulation with Decreased Mortality in Patients with Pulmonary Embolism Following Implementation of Artificial Intelligence Software

Matched‐pair and propensity score comparisons of outcomes of patients with clinical stage I non–small cell lung cancer treated with resection or stereotactic radiosurgery

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial

Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B

Why plasma‐derived factor VIII?

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

Postmastectomy Radiation Therapy and Breast Reconstruction: An Analysis of Complications and Patient Satisfaction

Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy

Matched-pair comparison of outcome of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery

Arbeiterbewegung von rechts?: Ungleichheit - Verteilungskämpfe - populistische Revolte

Suchergebnisse filtern